ACIP RECOMMENDS ROTAVIRUS VACCINATION TO HELP PROTECT INFANTS6
ACIP recommendation for rotavirus vaccination6
The ACIP recommends routine vaccination of US infants at least 6 weeks of age with a rotavirus vaccine.6
In addition to the ACIP, the AAFP and AAP recommend routine rotavirus vaccination for all eligible infants in order to protect infants against rotavirus and reduce rotavirus morbidity.6,12,13
aCan be completed as early as 14 weeks of age (doses given at 6, 10, and 14 weeks of age). Third dose should not be given after 32 weeks of age. The safety and efficacy of RotaTeq have not been established in infants less than 6 weeks of age or greater than 32 weeks of age.
AAFP, American Academy of Family Physicians; AAP, American Academy of Pediatrics; ACIP, Advisory Committee on Immunization Practices; CDC, Centers for Disease Control and Prevention.
Despite vaccination rates of approximately 75%, there’s still more to do14
children in the US has not been vaccinated against rotavirus.
National Immunization Survey-Child, United States, 2017-2021. Children born during 2018 and 2019 (N=29,598).
bUS counties mapped in green had both low vaccination rates and high rotavirus-related visit rates in a single month between 2015-2017.15
cIn 2015-2017, the national rotavirus vaccination rate, calculated using 1996-2017 data from a large US national insurance claims database, was 70%. Rotavirus-related hospital visit rates in counties with vaccination rates less than 70% were 5 times higher than the national average (1 per 1,000 eligible population).15
RGE, rotavirus gastroenteritis.
Helpful information for parents
Parents may feel overwhelmed with the number of vaccines their baby will receive in the first few months. Here is a helpful resource that you can give them that may help.
Vaccines for Children (VFC) Program
RotaTeq is well established in the VFC Program. Sign up to participate and help provide all routine vaccinations recommended by the CDC’s ACIP to your eligible patients.7
Dosing and Administration
Review the dosing schedule and administration of RotaTeq.
Rotavirus Strain Coverage
Learn why broad coverage matters and how RotaTeq helps protect against RGE caused by various strains of rotavirus.1Reference
Reference
Reference
Reference
Reference
Reference
Reference
Reference
Indications and Usage for RotaTeq
RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.
The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.
Selected Safety Information for RotaTeq
RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.
Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.
Infants with a history of intussusception should not receive RotaTeq.
No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.
In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.
No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.
Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.
In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.
In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.
RotaTeq may not protect all vaccine recipients against rotavirus.
Before administering RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent), please read the accompanying Prescribing Information. The Patient Product Information also is available.
Indications and Usage for RotaTeq
RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.
The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.
RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children
RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.
Selected Safety Information for RotaTeq
RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.
Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.
Infants with a history of intussusception should not receive RotaTeq.
No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.
In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.
No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.
Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.
In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.
In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.
RotaTeq may not protect all vaccine recipients against rotavirus.
Before administering RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent), please read the accompanying Prescribing Information. The Patient Product Information also is available.
RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity
RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.
Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged